Platinum-based chemotherapy was concurrently administered for 44 (62%) patients. 3/5-year overall survival (OS) rate and progression-free survival (PFS) rate were 64/50% and 40/37%, respectively. Membranous expression of PD-L1 was positive in 8.5% of patients, and not associated with prognosis. The presence of tumor-infiltrating T cell positive for CD8 (CD8+TILs) in the tumor nest was positive in 83% of patients, and associated with favorable OS ($p=0.037$) but not with PFS ($p=0.52$). A Cox regression analysis showed that the presence of CD8+TILs was an independent predictor of favorable OS (hazard ratio=0.19; 95% confidence interval=0.065–0.57) as well as lower International Federation of Gynecology and Obstetrics stage (2008, I–II vs. III–IVA), maximum tumor diameter smaller than 40 mm, and use of concurrent chemotherapy.

Conclusion: We reported clinical outcomes of CA after definitive RT and expression of immune-related molecules using biopsy sample. Our findings suggested that CD8+TILs in the tumor nest was a potential predictor of favorable prognosis, although prognostic impact of membranous PD-L1 expression was unclear.

Oral (OC7)

Preinvasive Disease of Cervix, Vulva, and Vagina
<https://doi.org/10.3802/jgo.2021.32.S1.OC7>

Prognostic outcomes and risk factors for recurrence after laser vaporization for cervical intraepithelial neoplasia: a single-center retrospective study

Keisuke Kodama,¹ Hideaki Yahata,^{1,*} Kaoru Okugawa,¹ Hiroshi Yagi,¹ Masafumi Yasunaga,¹ Tatsuhiko Ohgami,¹ Ichiro Onoyama,¹ Kazuo Asanoma,¹ Mototsugu Shimokawa,² Kiyoko Kato¹

¹Kyushu University, Fukuoka, Japan (hyahata@med.kyushu-u.ac.jp)

²Yamaguchi University, Yamaguchi, Japan

Objective: Cervical intraepithelial neoplasia (CIN) is a precancerous lesion that may progress to invasive cervical cancer without intervention. We aim to examine the prognostic outcomes and risk factors for recurrence after laser vaporization for CIN 3, CIN 2 with high-risk human papillomavirus (HPV) infection, and CIN 1 persisting for more than 2 years.

Methods: Between 2008 and 2016, a total of 1,070 patients underwent cervical laser vaporization using a carbon dioxide laser. We performed a retrospective review of their medical records to assess their clinical characteristics, pathologic factors, and prognostic outcomes.

Results: The mean patient age was 34 years (range, 18–64 years). The preoperative diagnosis was CIN 1 in 27 patients, CIN 2 in 485 patients, and CIN 3 in 558 patients. Over a median

follow-up period of 15 months, the 2-year recurrence rate was 18.9%, and the 5-year recurrence rate was 46.5%. The 2-year retreatment rate was 12.6%, and the 5-year retreatment rate was 30.5%. We diagnosed 9 patients with invasive cancer after treatment; all patients underwent combined multidisciplinary treatment, and there were no deaths during follow-up. The recurrence-free interval was correlated with patient age (hazard ratio [HR]=1.028; 95% confidence interval [CI]=1.005–1.051; $p=0.0167$), body mass index (HR=1.052; 95% CI=1.008–1.098; $p=0.0191$), and glandular involvement (HR=1.962; 95% CI=1.353–2.846; $p=0.0004$).

Conclusion: Cervical laser vaporization is effective and useful for patients with CIN who wish to preserve fertility. However, patients with glandular involvement, older age, and higher body weight require close follow-up for recurrence.

Uterine corpus cancer

Oral (OM1)

Endometrial Hyperplasia, Endometrial Intra-epithelial Neoplasia, and Endometrial Cancer
<https://doi.org/10.3802/jgo.2021.32.S1.OM1>

The real-world experience of pembrolizumab and lenvatinib in recurrent endometrial cancer: a multicenter study in South Korea

Junhwan Kim,¹ Joseph J. Noh,² Tae Kyoung Lee,³ Se Ik Kim,¹ Jung-Yun Lee,³ Jeong-Won Lee,² Jae-Weon Kim^{1,*}

¹Department of Obstetrics and Gynecology, Seoul National University College of Medicine, Seoul, Korea (kjksh@snu.ac.kr)

²Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea

³Department of Obstetrics and Gynecology, Women's Cancer Center, Institute of Women's Life Medical Science, Yonsei University College of Medicine, Seoul, Korea

Objective: To investigate real-world experience of pembrolizumab and lenvatinib (PEMBRO+LEN) in patients with recurrent endometrial cancer in South Korea.

Methods: This retrospective cohort study included patients with recurrent endometrial cancer who received PEMBRO+LEN from January 2020 to May 2021 in three tertiary hospitals in South Korea. We summarized patient characteristics and evaluated response rates, survival outcomes, and treatment-related adverse events (AEs).

Results: In total, 48 patients were included in the study. The median age was 62.5 (42–78) years. The most common histologic subtype was endometrioid (43.8%) followed by serous (25.0%). Most patients were MMR proficient (91.7%). Programmed death-ligand 1 and P53 status were positive